What is
Niraparib
?
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
Function of
Niraparib
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer..
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Application of
Niraparib
It is mainly used for the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and maintenance treatment of adult patients who have fully or partially responded to platinum chemotherapy drugs.